NL-OMON42319CompletedNot Applicable
A double-blind, placebo controlled, randomised, parallel group study with an open-label cross-over part, investigating safety, tolerability, pharmacokinetics, and pharmacodynamics after single ascending oral doses and a single intravenous dose of the vasopressin V2-receptor agonist FE 202217 - FE 202217 SAD and cross-over study
PRA Health Sciences0 sites52 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 52
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •- healthy male or female
- •- 18-45 years old inclusive
- •- BMI between 18.5 - 29.9 kg/m2
- •- non smoker
Exclusion Criteria
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90
- •days before the start of this study or being a blood donor within 60 days from the start of the study. In case of
- •donating more than 1.5 liters of blood in the 10 months prior the start of this study
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A double-blind, placebo controlled, randomised, parallel group phase IIa study to investigate the efficacy, tolerability, and safety of different dosing regimens of AZD8848 administered intranasally to seasonal allergic rhinitis patients out of pollen season in a nasal allergen challenge modelMedDRA version: 12.1Level: LLTClassification code 10001723Term: Allergic rhinitisAllergic RhinitisEUCTR2010-020747-13-SEAstraZeneca AB
Active, not recruiting
Phase 1
A double-blind, placebo controlled, randomised, parallel group, single centre, phase IIa study to investigate the efficacy, tolerability and safety of 8 doses of AZD8848 administered intranasally once weekly in mild to moderate allergic asthma patients challenged with an inhaled allergen.MedDRA version: 12.0 Level: LLT Classification code 10001705 Term: Allergic asthmaAllergic AsthmaEUCTR2009-013705-34-GBAstraZeneca AB
Completed
Not Applicable
A double-blind, placebo controlled, randomised, parallel group study with an open-label cross-over part, investigating safety, tolerability, pharmacokinetics, and pharmacodynamics after single ascending oral doses and a single intravenous dose of the vasopressin V2-receptor agonist FE 201836octurianight voidingNL-OMON43629Ferring76
Completed
Not Applicable
A clinical study to evaluate the efficacy and safety of Libidolyn�® when compared with placebo in improving sexual health of male subjects.CTRI/2022/03/041069Herbalyn Lifesciences Inc60
Completed
Not Applicable
This is a study to evaluate the efficacy and safety of Slimilyn�® Capsules verses placebo in overweight and obese adult subjects.CTRI/2022/03/040987Herbalyn Lifesciences Inc60